Advances in Castration-Resistant Prostate Cancer Treatment
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 27 February 2025 | Viewed by 186
Special Issue Editors
Interests: triple-negative breast cancers; hormone-receptor-positive breast cancers; drug resistance; dormancy; metastasis
Special Issues, Collections and Topics in MDPI journals
Interests: oncogenes; drug combinations; biomarkers; chemoprevention; small-molecule inhibitors
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The androgen receptor (AR) is a transcriptional factor and plays a predominant role in prostate cancer (PCa) pathology. Hence, most PCa therapies target AR, specifically the ligand-binding domain of AR. Androgen deprivation by castration through surgery or medical treatment reduces androgen levels, resulting in prostatic atrophy and prostate cancer regression. However, regrading androgen deprivation therapies (ADT), though initially successful, their efficacy is limited, and tumor recurrence occurs frequently, eventually leading to the progression of castration-resistant prostate cancer (CRPC). Moreover, anti-androgens such as abiraterone and enzalutamide are resistant to CRPC due to the emergence of AR splice variants (AR-SVs) that lack the ligand-binding domain (LBD). Consequently, there is an urgent clinical need to develop novel therapeutic strategies for the treatment of prostate cancer.
This Special Issue provides an extensive overview of recent advances in the development of targeted therapy for prostate cancer treatment, along with new strategies in basic and translational research. Understanding the molecular intricacies of the AR signaling pathways involved in prostate cancer progression will aid the development of competent targeted therapies that can be translated to clinics.
Dr. Eswar Shankar
Dr. Balaji Chandrasekaran
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- androgen receptor
- CRPC
- chemoresistance
- combination therapy
- small molecules
- chemoprevention
- ubiquitination
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
